Search Results 391-400 of 16021 for SC

  1. Lymphoma - Symptoms and causes - Mayo Clinic

    Find out more about the symptoms, diagnosis and treatment of this cancer of the lymphatic system.

  2. Omalizumab (subcutaneous route) - Mayo Clinic

    Omalizumab injection is used to treat moderate to severe persistent allergic asthma. It is used when a patient's asthma has not been controlled sufficiently on ...

  3. Publications - Leland S. Hu, M.D. - Mayo Clinic

    ... SC, LoCastro E, Paudyal R, Wolansky IA, Shukla-Dave A, Schouten P, Gurney-Champion OJ, Jirik R, Macicek O, Bartos M, Vitous J, Das AB, Kim SG, Bokacheva L ...

  4. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma - Mayo Clinic

    The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed ...

  5. Publications - John J. Lucido, III, Ph.D. - Mayo Clinic

    ... SC, Rule WG, Deufel CL, Foster MG. Development and Dosimetric Characterization of a Customizable Shield for Subtotal Skin Electron Beam Therapy. Adv Radiat ...

  6. David D. Thiel, M.D. - Doctors and Medical Staff - Mayo Clinic

    ... S.C.. 2005. T. Leon Howard Pyelogram Conference - 1st place, Uterine adenosarcoma in a boy with PMDS69th Annual Southeast Section Meeting of the AUA ...

  7. Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) - Mayo Clinic

    The purpose of this multinational, randomized, placebo-controlled, and double blind study is to evaluate the safety and efficacy of subcutaneous (SC) ...

  8. A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    ... [SC] or intramuscular ... at least one 2-week induction regimen of golimumab (one 200 mg SC dose followed by one 100 mg SC dose at least 2 weeks apart); ...

  9. Publications - Laura E. Breeher, M.D., M.P.H. - Mayo Clinic

    ... SC. A Multisite Assessment of Inpatient Safety Event Rates During the Coronavirus Disease 2019 Pandemic. Mayo Clin Proc Innov Qual Outcomes. 2023 Feb; 7 (1): ...

  10. A 2-stage, Phase III Study To Investigate The Efficacy And Safety Of Anifrolumab In Adults With Chronic And/​or Subacute Cutaneous Lupus Erythematosus (LAVENDER) - Mayo Clinic

    This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus ( ...